Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Hilton Worldwide Holdings Inc. (HLT) - free report >>
Aramark (ARMK) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hilton Worldwide Holdings Inc. (HLT) - free report >>
Aramark (ARMK) - free report >>
Image: Bigstock
New Strong Sell Stocks for January 20th
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Ituran Location and Control Ltd. (ITRN - Free Report) provides location-based services and wireless communications products. The Zacks Consensus Estimate for its current year earnings has been revised nearly 6% downward over the last 30 days.
NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 4.8% downward over the last 30 days.
Hilton Worldwide Holdings Inc. (HLT - Free Report) is a hospitality company that owns, leases, manages, develops, and franchises hotels and resorts. The Zacks Consensus Estimate for its current year earnings has been revised 5.6% downward over the last 30 days.
Aramark (ARMK - Free Report) provides food, facilities, and uniform services to education, healthcare, business and industry, sports, leisure, and corrections client. The Zacks Consensus Estimate for its current year earnings has been revised 4.4% downward over the last 30 days.
ProQR Therapeutics N.V. (PRQR - Free Report) is a biopharmaceutical company that engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. The Zacks Consensus Estimate for its current year earnings has been revised nearly 1% downward over the last 30 days.
View the entire Zacks Rank #5 List.